AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20739426 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin supplementation
Number of subjects: 594
Study 20739426 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 594
Study 18278679 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimized extracorporeal circulation
Number of subjects: 60
Study 18278679 — intervention group
Group type: COMPARATOR
Intervention: Standard extracorporeal circulation
Number of subjects: 60
Study 18278679 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 15747808 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid maxillary expansion (RME) in early-treated group (group I T)
Number of subjects: 29
Study 15747808 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid maxillary expansion (RME) in late-treated group (group II T)
Number of subjects: 29
Study 15747808 — intervention group
Group type: COMPARATOR
Intervention: Control group (early-control group I C)
Number of subjects: 29
Study 15747808 — intervention group
Group type: COMPARATOR
Intervention: Control group (late-control group II C)
Number of subjects: 29
Study 12703668 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium (Mg) 732 mg/day
Number of subjects: 18
Study 12703668 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 10337546 — intervention group
Group type: EXPERIMENTAL
Intervention: Left atrioventricular plane displacement
Number of subjects: 54
Study 10337546 — intervention group
Group type: EXPERIMENTAL
Intervention: Log‐1 Edt
Number of subjects: 54
Study 10337546 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional shortening
Number of subjects: 54
Study 7473964 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection into the antecubital fossa
Number of subjects: 100
Study 7473964 — intervention group
Group type: COMPARATOR
Intervention: Injection into the dorsum of the hand
Number of subjects: 100
Study 2029037 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtered water (reverse-osmosis)
Number of subjects: 606
Study 2029037 — intervention group
Group type: COMPARATOR
Intervention: Tapwater without a filter
Number of subjects: 606
Study 7447362 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzyl penicillin
Number of subjects: 147
Study 7447362 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin + gentamicin
Number of subjects: 147
Study 7447362 — intervention group
Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 147
Study 7447362 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 147
Study 31633580 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual feedback training with visual targets on gradual weight shifting
Number of subjects: 21
Study 31633580 — intervention group
Group type: COMPARATOR
Intervention: Visual feedback training on gradual weight shifting
Number of subjects: 21
Study 29402157 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligation of internal iliac arteries (IIA)
Number of subjects: 54
Study 29402157 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporary occlusion of common iliac artery (CIA)
Number of subjects: 54
Study 29402157 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined compression hemostasis
Number of subjects: 54
Study 29402157 — intervention group
Group type: EXPERIMENTAL
Intervention: All surgical techniques
Number of subjects: 54
Study 28464270 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 18
Study 28464270 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 25868737 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal epididymal cystectomy with scrotoscope (MECS)
Number of subjects: 48
Study 25868737 — intervention group
Group type: COMPARATOR
Intervention: Traditional open epididymal cystectomy (OEC)
Number of subjects: 48
Study 23962993 — intervention group
Group type: EXPERIMENTAL
Intervention: Riluzole combined with surgical decompression
Number of subjects: 0
Study 23962993 — intervention group
Group type: COMPARATOR
Intervention: Surgical decompression
Number of subjects: 0
Study 21245205 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based ambulation training (1 hour, once a day, three times a week for 4 weeks)
Number of subjects: 25
Study 21245205 — intervention group
Group type: COMPARATOR
Intervention: Routine physical therapy
Number of subjects: 25
Study 19234720 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of antibodies against BCL-2 in patients' sera
Number of subjects: 95
Study 19234720 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-BCL-2 antibodies
Number of subjects: 95
Study 18184536 — intervention group
Group type: EXPERIMENTAL
Intervention: Meracilina/Pen‐Ve‐Oral 500,000 UI
Number of subjects: 26
Study 15369506 — intervention group
Group type: EXPERIMENTAL
Intervention: REMUNE therapy every 12 weeks for 132 weeks
Number of subjects: 223
Study 15369506 — intervention group
Group type: EXPERIMENTAL
Intervention: REMUNE therapy
Number of subjects: 223
Study 15369506 — intervention group
Group type: EXPERIMENTAL
Intervention: REMUNE monotherapy or REMUNE plus antiretrovirals (ARTs)
Number of subjects: 223
Study 10875859 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 microg desogestrel
Number of subjects: 30
Study 10875859 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 microg desogestrel
Number of subjects: 30
Study 10875859 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 microg desogestrel
Number of subjects: 30
Study 10875859 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (300 mg)
Number of subjects: 30
Study 10875859 — intervention group
Group type: COMPARATOR
Intervention: Control group (no desogestrel)
Number of subjects: 30
Study 9104523 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg.kg-1 propofol
Number of subjects: 70
Study 9104523 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intralipid 10%)
Number of subjects: 70
Study 8251277 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA with background infusion of morphine 20 micrograms kg‐1 h‐1
Number of subjects: 40
Study 8251277 — intervention group
Group type: COMPARATOR
Intervention: PCA only (bolus dose 20 micrograms kg‐1 with a lockout interval of 5 min)
Number of subjects: 40
Study 8251277 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA with background infusion of morphine
Number of subjects: 40
Study 3697654 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy
Number of subjects: 322
Study 3697654 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (CMF)
Number of subjects: 322
Study 3697654 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy followed by chemotherapy
Number of subjects: 322
Study 3697654 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 322
Study 28425562 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention for relationship distress
Number of subjects: 300
Study 28425562 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 300
Study 26439829 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 28
Study 26439829 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 28
Study 24903985 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic decision support tools for intensified secondary prevention for 12 months
Number of subjects: 11391
Study 24903985 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 11391
Study 23100609 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental report of adherence
Number of subjects: 132
Study 23100609 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental report of reasons for non-adherence
Number of subjects: 132
Study 20980643 — intervention group
Group type: EXPERIMENTAL
Intervention: Red meat intervention (n = 90)
Number of subjects: 225
Study 20980643 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified manufactured toddler milk drink (FTMD) intervention (n = 45)
Number of subjects: 225
Study 20980643 — intervention group
Group type: COMPARATOR
Intervention: Nonfortified milk placebo (n = 90)
Number of subjects: 225
Study 19021989 — intervention group
Group type: EXPERIMENTAL
Intervention: Mononuclear bone marrow cell (MN‐BMC) transplantation, mean number of 6.59 x 10(8) +/- 5.12 x 10(8) MN‐BMC injected during CABG
Number of subjects: 36
Study 19021989 — intervention group
Group type: COMPARATOR
Intervention: Control group (CABG alone)
Number of subjects: 36
Study 16385751 — intervention group
Group type: EXPERIMENTAL
Intervention: After-school physical activity program
Number of subjects: 278
Study 12420619 — intervention group
Group type: EXPERIMENTAL
Intervention: Algosteril (calcium alginate) dressing
Number of subjects: 67
Study 12420619 — intervention group
Group type: COMPARATOR
Intervention: Jelonet (paraffin gauze) dressing
Number of subjects: 67
Study 9442170 — intervention group
Group type: EXPERIMENTAL
Intervention: 17 beta‐oestradiol eye drops (n = 42, group 1)
Number of subjects: 84
Study 9442170 — intervention group
Group type: COMPARATOR
Intervention: Tear substitute (n = 42, group 2)
Number of subjects: 84
Study 8584072 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASS) at dosages of > or = 975 mg per day
Number of subjects: 0
Study 8584072 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASS) at dosages of about 300 mg per day
Number of subjects: 0
Study 8584072 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASS) at dosages of < or = 100 mg per day
Number of subjects: 0
Study 8584072 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2234995 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA (topical anesthetic)
Number of subjects: 28
Study 346607 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Relaxation Training (PRT)
Number of subjects: 30
Study 346607 — intervention group
Group type: EXPERIMENTAL
Intervention: Meditation Training (MT)
Number of subjects: 30
Study 346607 — intervention group
Group type: COMPARATOR
Intervention: Quiet Rest (QR)
Number of subjects: 30
Study 30395000 — intervention group
Group type: EXPERIMENTAL
Intervention: ED trigger tool
Number of subjects: 2594
Study 31493749 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 89
Study 31493749 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirit only MI (SOMI)
Number of subjects: 89
Study 31493749 — intervention group
Group type: COMPARATOR
Intervention: Non-therapy control
Number of subjects: 89
Study 30006024 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis C-Alcohol Reduction Treatment (Hep ART) intervention
Number of subjects: 0
Study 30006024 — intervention group
Group type: COMPARATOR
Intervention: Enhanced treatment as usual (TAU)
Number of subjects: 0
Study 26639204 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel plus bivalirudin
Number of subjects: 71
Study 26639204 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel plus heparin
Number of subjects: 71
Study 24558093 — intervention group
Group type: EXPERIMENTAL
Intervention: PBMC nascent proteome
Number of subjects: 0
Study 24558093 — intervention group
Group type: EXPERIMENTAL
Intervention: PBMC total proteome
Number of subjects: 0
Study 24558093 — intervention group
Group type: COMPARATOR
Intervention: Matched controls (not specified how many)
Number of subjects: 0
Study 22246331 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin 0.3%
Number of subjects: 42
Study 22246331 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 42
Study 19875761 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti‐CD20 monoclonal antibody therapy
Number of subjects: 0
Study 19875761 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (anthracycline‐based)
Number of subjects: 0
Study 19875761 — intervention group
Group type: EXPERIMENTAL
Intervention: FOXP3 cells and LAMs
Number of subjects: 0
Study 17376250 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal tube
Number of subjects: 132
Study 17376250 — intervention group
Group type: COMPARATOR
Intervention: Laryngeal mask
Number of subjects: 132
Study 15797671 — intervention group
Group type: EXPERIMENTAL
Intervention: Inulin-fortified beverages (13 g/d)
Number of subjects: 0
Study 15797671 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric standard modified starch-thickened beverages
Number of subjects: 0
Study 12019107 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (AZT) at 250 to 300 mg twice daily, 3TC at 150 mg twice daily, and indinavir at 800 mg every 8 h
Number of subjects: 170
Study 12019107 — intervention group
Group type: COMPARATOR
Intervention: Stavudine (d4T) at 40 mg twice daily, 3TC at 150 mg twice daily, and indinavir at 800 mg every 8 h
Number of subjects: 170
Study 12019107 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (AZT)
Number of subjects: 170
Study 12019107 — intervention group
Group type: COMPARATOR
Intervention: Stavudine (d4T)
Number of subjects: 170
Study 12019107 — intervention group
Group type: EXPERIMENTAL
Intervention: Both AZT and d4T arms
Number of subjects: 170
Study 9824171 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term anxiety-provoking psychotherapy (STAPP)
Number of subjects: 20
Study 9824171 — intervention group
Group type: COMPARATOR
Intervention: Nondirective therapy with common factors of psychotherapy
Number of subjects: 20
Study 9824171 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (STAPP and nondirective therapy)
Number of subjects: 20
Study 9824171 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic alliance
Number of subjects: 20
Study 8120917 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRHA-based contraceptive regimen (7.5 mg leuprolide acetate depot every 28 days, 0.625 mg conjugated estrogen for 6 days each week, 10 mg medroxyprogesterone acetate for 13 days every fourth cycle)
Number of subjects: 21
Study 8120917 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRHA-based contraceptive regimen
Number of subjects: 21
Study 8120917 — intervention group
Group type: COMPARATOR
Intervention: Control group (no medication)
Number of subjects: 21
Study 2683658 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 ml/kg of iohexol
Number of subjects: 59
Study 2683658 — intervention group
Group type: COMPARATOR
Intervention: 0.8 ml/kg of iohexol
Number of subjects: 59
Study 1098887 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release aminophylline (350 mg, released over eight hours)
Number of subjects: 26
Study 295486 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% NaF + 2% chlorhexidine
Number of subjects: 91
Study 295486 — intervention group
Group type: COMPARATOR
Intervention: 2% chlorhexidine
Number of subjects: 91
Study 295486 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% NaF
Number of subjects: 91
Study 31752975 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive educational intervention (video fragments, discussion, quizzes with tailored feedback, exercise filling out a registration form) during two 50-min lessons.
Number of subjects: 1170
Study 31752975 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 1170
Study 30096107 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,550-nm Er:Glass fractional laser treatment
Number of subjects: 23
Study 27637770 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation (FES) cycling program, five times a week over a 4-week period, in addition to usual care.
Number of subjects: 40
Study 27637770 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone.
Number of subjects: 40
Study 23829785 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D-fortified doogh (DD; containing 150 mg of calcium + 500 IU vitamin D per 250 mL)
Number of subjects: 90
Study 23829785 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium-vitamin D-fortified doogh (CDD; containing 250 mg of calcium + 500 IU vitamin D per 250 mL)
Number of subjects: 90
Study 23829785 — intervention group
Group type: COMPARATOR
Intervention: Plain doogh (PD; containing 150 mg per 250 mL of calcium and no detectable vitamin D)
Number of subjects: 90
Study 23829785 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium-vitamin D-fortified doogh (CDD)
Number of subjects: 90
Study 23829785 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D-fortified doogh (DD)
Number of subjects: 90
Study 23829785 — intervention group
Group type: COMPARATOR
Intervention: Plain doogh (PD)
Number of subjects: 90
Study 22563020 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFN/RBV
Number of subjects: 329
Study 22563020 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 329
Study 19317579 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular Aneurysm Repair (EVAR) with Zenith stent-graft (CAESAR trial)
Number of subjects: 1765
Study 19317579 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular Aneurysm Repair (EVAR) with AneuRx or Talent stent-grafts (PIVOTAL trial)
Number of subjects: 1765
Study 19317579 — intervention group
Group type: COMPARATOR
Intervention: Surveillance (CAESAR trial)
Number of subjects: 1765
Study 19317579 — intervention group
Group type: COMPARATOR
Intervention: Surveillance (PIVOTAL trial)
Number of subjects: 1765
Study 17161655 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation fecal DNA assay (version 2) with improved DNA stabilization/isolation techniques and new promoter methylation marker.
Number of subjects: 162
Study 17161655 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of vimentin methylation plus DNA integrity assay (DIA).
Number of subjects: 162
Study 17161655 — intervention group
Group type: COMPARATOR
Intervention: Prototype fecal DNA assay (version 1).
Number of subjects: 162
Study 15732871 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet concentrate grafts (PCG)
Number of subjects: 15
Study 15732871 — intervention group
Group type: COMPARATOR
Intervention: Subepithelial connective tissue grafts (SCTG)
Number of subjects: 15
Study 12379887 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF treatment started on day 6 post transplant
Number of subjects: 42
Study 12379887 — intervention group
Group type: COMPARATOR
Intervention: G-CSF treatment started on day 9 post transplant
Number of subjects: 42
Study 9805219 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-saturated fat high-carbohydrate diet (22%, 6%, and 59% energy from total, saturated, and carbohydrate, respectively)
Number of subjects: 38
Study 9805219 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-saturated fat high-carbohydrate diet
Number of subjects: 38
Study 9805219 — intervention group
Group type: COMPARATOR
Intervention: Traditional Western diet (36%, 18%, and 43% energy from total, saturated, and carbohydrate, respectively)
Number of subjects: 38
Study 7653803 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infused to maintain EEG burst suppression
Number of subjects: 30
Study 7653803 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil and vecuronium (control group)
Number of subjects: 30
Study 2757327 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal suppositories of PDRN (5g preparation)
Number of subjects: 20
Study 2757327 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal suppositories of PDRN (10g preparation)
Number of subjects: 20
Study 3963 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol (Trasicor)
Number of subjects: 11
Study 3963 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol (Trasicor) + cyclopenthiazide
Number of subjects: 11
Study 3963 — intervention group
Group type: COMPARATOR
Intervention: Cyclopenthiazide
Number of subjects: 11
Study 31972601 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus human albumin 5%
Number of subjects: 60
Study 31972601 — intervention group
Group type: COMPARATOR
Intervention: Bolus ringer acetate 250 ml
Number of subjects: 60
Study 31972601 — intervention group
Group type: EXPERIMENTAL
Intervention: Other haemodynamic variables
Number of subjects: 60
Study 31972601 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid-related complications
Number of subjects: 60
Study 31972601 — intervention group
Group type: EXPERIMENTAL
Intervention: Length of stay (LOS) in ICU and hospital
Number of subjects: 60
Study 29331656 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal turning practices influenced by real-time data from a wearable patient sensor (treatment group, n=659)
Number of subjects: 1312
Study 29331656 — intervention group
Group type: COMPARATOR
Intervention: Traditional turn reminders and standard practices (control group, n=653)
Number of subjects: 1312
Study 27481621 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive threshold (transfuse if haemoglobin <7.5 g/dL)
Number of subjects: 2003
Study 27481621 — intervention group
Group type: COMPARATOR
Intervention: Liberal threshold (transfuse if haemoglobin <9 g/dL)
Number of subjects: 2003
Study 24246541 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based and supervised exercise programs (intermittent walking to near maximal claudication pain for 3 months)
Number of subjects: 80
Study 24246541 — intervention group
Group type: COMPARATOR
Intervention: Control group (diabetic women)
Number of subjects: 80
Study 22052867 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 g/day each of d‐pantothenic acid and l‐cysteine (CP)
Number of subjects: 8
Study 22052867 — intervention group
Group type: COMPARATOR
Intervention: Placebo control (glucose polymer; CON)
Number of subjects: 8
Study 22052867 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CP and CON
Number of subjects: 8
Study 20394255 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 1 mg and dexamethasone 8 mg
Number of subjects: 100
Study 20394255 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron 4 mg and dexamethasone 8 mg
Number of subjects: 100
Study 18514877 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromagnetic (EM) navigation system
Number of subjects: 46
Study 18514877 — intervention group
Group type: COMPARATOR
Intervention: Infrared (IR) navigation system
Number of subjects: 46
Study 16425830 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial basis function artificial neural networks (RBF ANN) for control of neural prosthesis
Number of subjects: 0
Study 16425830 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional electrical therapy (FET)
Number of subjects: 0